Congress Took Funding for Global COVID-19 Vaccinations Off the Table. More Than Half of Voters Say It Should Be a Priority

Voters more likely to back funding for U.S. vaccinations than those overseas
April 13, 2022 at 6:00 am UTC

As the Biden administration’s pandemic response evolves, most registered voters say they want the federal government to fund COVID-19 vaccinations in both the United States and overseas, according to a new Morning Consult/Politico survey.

What you need to know

  • Voters broadly back additional funding for COVID-19 vaccinations in the United States, with 85% of Democrats and 54% of Republicans saying it should be a “top” or “important but lower” priority for the federal government.
  • While voters of both parties were less likely to say the government should prioritize international vaccinations, support among GOP voters for more funding in low-income countries and across the globe more generally saw double-digit drops. About 3 in 4 Democrats said global funding for shots should be a priority.
  • The findings come as a bipartisan deal for an additional $10 billion for the federal pandemic response remains stalled in Congress through the Easter holiday. Earlier, Senate negotiators dropped support for global vaccinations from the deal, leading health officials to warn that their work to help vaccinate the world could be hampered in the coming months.
  • The White House has also said that without more funding from Congress, the federal government doesn’t have the money to buy enough COVID-19 shots for all Americans to get a fourth dose. Federal vaccine advisers are scrambling to put together a framework for potential booster shots this fall.
  • The scope of the international vaccine campaign is shifting. The global vaccine-sharing initiative COVAX, which has delivered 1.42 billion COVID-19 vaccine doses to 145 countries, said last week it has raised $4.8 billion, just short of its $5.2 billion target, as officials grapple with demand and distribution challenges rather than supply shortages. COVAX and the African Union also recently turned down the option to buy more of Moderna Inc.’s shots.


The April 8-11, 2022, survey was conducted among a representative sample of 2,005 registered voters, with an unweighted margin of error of plus or minus 2 percentage points.

A headshot photograph of Gaby Galvin
Gaby Galvin

Gaby Galvin previously worked at Morning Consult as a reporter covering health.

We want to hear from you. Reach out to this author or your Morning Consult team with any questions or comments.Contact Us